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Background: The etiology of inflammatory myofibroblastic tumors (IMTs) is controversial and the prognosis is
unpredictable. Previous studies have not investigated the expression of hypoxia-related markers in IMTs.
Methods: Between 2002 and 2012, 12 consecutive patients with histologically proven IMTs were enrolled in the
study. Immunohistochemistry was used to detect GLUT-1, HIF-1α, PI3K, and p-Akt expression in paraffin-embedded
tumor specimens. Associations among GLUT-1, HIF-1α, PI3K, and p-Akt protein expression and clinical parameters
were investigated.
Results: The mean duration of follow-up was 52.1 months (range, 11 to 132 months). Six patients had local recurrence.
GLUT-1, HIF-1α, PI3K, and p-Akt expression were detected in 41.7%, 50.0%, 33.3%, and 41.7% of patients, respectively.
Fisher’s exact test revealed significant correlations between recurrence of IMT and PI3K expression (P = 0.01) and p-Akt
expression (P = 0.015). Univariate analyses revealed significant correlations between survival and GLUT-1 expression
(P = 0.028), PI3K expression (P = 0.006), and p-Akt expression (P = 0.028). Multivariate analysis did not show a significant
relationship between survival and GLUT-1, HIF-1α, PI3K, or p-Akt. Spearman rank correlation analysis showed significant
correlations between HIF-1α and PI3K expression (r = 0.707, P = 0.01) and between p-Akt and PI3K expression (r = 0.837,
P = 0.001).
Conclusions: Although our results are inconclusive owing to the small sample size, they suggest that PI3K and p-Akt
expression may play a role in the recurrence of IMTs of the head and neck.
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Inflammatory myofibroblastic tumor (IMT) is an intermediated-
grade tumor, according to the World Health Organization-
classification, and has a potential for recurrence and rare
metastasis [1]. However, the etiology of IMT is controver-
sial, and its prognosis is unpredictable [2]. Previous studies,
including ours, have shown that the biological behavior of
the lesion is associated with location, cellar atypia, the pres-
ence of ganglion-like cells, p53, DNA aneuploidy, and ana-
plastic lymphoma kinase (ALK) [3,4]. However, evidence* Correspondence: zhouyunzhoush@163.com
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reproduction in any medium, provided the orthat these factors are prognostic markers is inconclusive. A
number of studies have found high 18 F-2-fluoro-2-deoxy-
D-glucose (18 F-FDG) uptake in IMTs [5,6]. Increased up-
take of FDG, a glucose analog, directly reflects a high
glucose metabolic rate in IMTs. Several studies have
demonstrated that glucose transporter-1(GLUT-1) plays a
significant role in the glucose metabolism of malignant tu-
mors and may contribute to increased FDG uptake [7-9].
GLUT-1 is thought to be an intrinsic marker of hypoxia in
some tumors [7-9]; however, the expression of hypoxia-
related markers has not been investigated in IMTs.
Hypoxia is a common pathophysiological condition in
tumors, caused by the tumor outgrowing its vascular sup-
ply [10]. Hypoxia is an independent negative prognostictd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Immunohistochemical molecular markers
Markers Source Dilution
GLUT-1 Santa Cruz Biotechnology 1:50
HIF-1α Santa Cruz Biotechnology 1:100
PI3K Santa Cruz Biotechnology 1:100
p-Akt Santa Cruz Biotechnology 1:100
ALK Dako, Carpinteria, CA, USA 1:100
Ki-67 Santa Cruz Biotechnology 1:100
Vimentin Dako, Carpinteria, CA, USA 1:100
S-100 protein Dako, Carpinteria, CA, USA 1:400
Desmin Dako, Carpinteria, CA, USA 1:100
α-SMA Dako, Carpinteria, CA, USA 1:5000
CD68 Dako, Carpinteria, CA, USA 1:300
CD34 Dako, Carpinteria, CA, USA 1:50
ALK, anaplastic lymphoma kinase; α-SMA, α-smooth muscle actin; GLUT-1,
glucose transporter-1; HIF, hypoxia-inducible factor.
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the behavior of the cancer cells [11]. Hypoxia-inducible
factor 1 (HIF-1) plays an important role during these pro-
cesses [12]. HIF-1 is composed of two subunits: HIF-1α
and HIF-1β. Under normoxia, HIF-1α is degraded by the
von Hippel-Lindau-dependent ubiquitin-proteasome path-
way [13]. However, it is rapidly stabilized under hypoxic
conditions. HIF-1α binds to the hypoxia-response elements
in the promoter region of target genes, including GLUT-1,
which mediate an increase in oxygen availability and en-
ergy supply, and enable metabolic adaptation to hypoxia
[14]. GLUT-1 expression increases under hypoxia, which is
consistent with findings of increased glucose uptake, in-
creased adaptive changes to glycolytic metabolism, and in-
creased cellular proliferation in cancer cells.
HIF-1α is upregulated in a wide range of solid tu-
mors in human beings, and overexpression of HIF-1α
is associated with tumor aggressiveness and poor prog-
nosis [15,16]. Thus, HIF-1α is a novel therapeutic tar-
get for several solid tumors [17,18]. However, the
mechanisms regulating HIF-1α activity are not well
understood. Oncogenic signaling pathways, such as the
phosphatidylinositol 3-kinase (PI3K)/protein kinase B
(Akt) pathway, may regulate HIF-1α [19]. Moreover,
the PI3K/Akt pathway has been shown to promote
GLUT-1 cell-surface trafficking and activity [20].
In this study, we used immunohistochemistry to deter-
mine the levels of PI3K, p-Akt, HIF-1α, and Glut-1 pro-
tein expression in IMTs of the head and neck and
assessed the relationship among these proteins.
Methods
Patients
The subjects were 12 consecutive patients treated be-
tween 2002 and 2012 at The First Affiliated Hospital
with histologically proven IMT. Data were obtained
from the hospital surgical pathology files. Our study was
approved by the Institutional Review Board of The First
Affiliated Hospital, College of Medicine, Zhejiang Uni-
versity, and written informed consent was obtained from
each patient before inclusion.
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed
paraffin-embedded tissue blocks prepared from biopsies
of the primary lesion of each subject. The biopsy tissue
was cut into 4-μm sections and analyzed using an EliVi-
sion™ Plus IHC kit (Fuzhou Maixin Biotechnology De-
velopment, China). Table 1 shows the primary antibody,
source, and dilution used. Briefly, the sections were
deparaffinized with xylene and dehydrated through an
ethanol series, then antigen retrieval was performed with
a microwave oven over two 10-min cycles. Endogenous
peroxidase activity was blocked by incubating the slidesin 1.5% hydrogen peroxide in absolute methanol at room
temperature for 10 min. Primary antibodies were applied
for 1 hour at room temperature, followed by 50 μl of
polymer enhancer for 20 min and 50 μl of polymerized
horseradish peroxidase-anti-mouse immunoglobulin G
(IgG) (DAB Kit; Maixin Biological) for 30 min. The reac-
tion products were visualized using 3,3′ diaminobenzi-
dine (DAB Kit; Maixin Biological), and the sections were
counterstained with hematoxylin and eosin, dehydrated,
and examined under a light microscope. Tris-buffered
saline was used in place of the primary antibody for
negative controls. Erythrocytes, which were present in
all sections, served as internal controls for GLUT-1 to
ensure constant immunostaining intensity.
GLUT-1, HIF-1α, PI3K, and p-Akt levels were evalu-
ated by the same investigator (H-TY), who was blinded
to the clinical and follow-up data. GLUT-1 expression
was considered positive only if distinct membrane stain-
ing was present. HIF-1α, PI3K, and p-AKT proteins
were observed in the nucleus and cytoplasm. Protein
analysis was performed in ten random high-power fields
within each of which 100 tumor cells were counted for
each case and for all antibodies. The percentage of posi-
tive cells was calculated by dividing the number of posi-
tive tumor cells by the total number of tumor cells
counted. A sample was considered negative if <25% of
the cells were stained.
Follow-up
The patients were scheduled for follow-up visits every
6 months after the initial surgery. Follow-up consisted of
a routine physical examination and computed tomog-
raphy (CT) or magnetic resonance imaging (MRI) of the
primary site. A combined 18 F-FDG positronemission
tomography (PET) and CT scan was performed on one
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last seen in the clinic.
Statistical analysis
The Statistical Package for the Social Sciences version
19 for Windows (SPSS Inc., Chicago, IL, USA) was used
to conduct the statistical tests. Associations among
GLUT-1, HIF-1α, PI3K, and p-Akt protein expression
and pretreatment clinical parameters were analyzed using
the chi-squared and Fisher’s exact tests. A P value <0.05
was deemed to indicate statistical significance. Correlation
analysis was performed using Spearman’s rank correlation.
Results and discussion
Patients’ characteristics
The clinicopathological findings (age, sex, tumor site, re-
currence, metastasis, and follow-up) are shown in Table 2.
The subjects included four men and eight women with a
mean age of 44.4 years (range, 22 to 64 years). Tumors
were located in the maxillary sinus (n = 4, 33.3%), tonsils
(n = 2, 16.7%), larynx (n = 1, 8.3%), hypopharynx (n = 1,
8.3%), maxillare (n = 1, 8.3%), tongue (n = 1, 8.3%), neck
(n = 1, 8.3%), and floor of the mouth (n = 1, 8.3%). No
fever, weight loss, malaise, or laboratory abnormality
(anemia, thrombocytosis, elevated erythrocyte sedimenta-
tion rate) was observed in any patient.
Available IMT radiological images varied. CT, MRI, or
FDG-PET/CT scans were available for nine patients. CT
images were available for eight patients and showed
homogenous (one case) or heterogeneous (seven cases)
softtissue masses. Contrast-enhanced CT images were
available for four patients: one case of IMT of the tonsil
showed no enhancement, mild enhancement was found
in one case of hypopharynx IMT, mild to moderate en-
hancement was detected in one of the maxillary sinus
cases, and the IMT of the tongue showed strong en-
hancement. MRI data were available for two patients. In
one patient, the T1-weighted signals were isointense and
slightly hypointense and the T2-weighted signals were
hyperintense. In the other patient, the T1 images were
hyperintense and the T2 images were hypointense. The
contrast-enhanced T1-weighted MRI images showed
heterogeneous enhancement in both patients (Figure 1).
FDG-PET/CT revealed FDG uptake in the left maxillary
sinus (Figure 2A).
Surgery was the initial treatment for all patients. Six
patients underwent complete excision to achieve a clear
margin. Local excision was performed on five patients
with IMT of the maxillary sinus (n = 5) and maxillare
(n = 1). Of those, two patients received corticosteroids
following surgery, one patient received postoperative
radiotherapy, and two patients receive no postopera-
tive adjuvant treatment. The IMT of the larynx was ex-
cised using suspension laryngoscopy.Follow-up ranged from 11 to 132 months (mean,
52.1 months). Six patients experienced local recurrence.
These patients had received local excision as the initial
treatment, indicating that local excision cannot guaran-
tee negative resection margins. Two of the patients who
experienced a local recurrence had cervical metastasis.
Five of the six patients underwent a second surgery. Of
those, three received total maxillectomy, and two of
these three received postoperative chemotherapy or radio-
therapy. One patient received a partial maxillectomy, and
one patient with a hypopharyngeal IMT underwent
complete resection via a lateral neck incision and achieved
a clear margin. One patient refused a second surgery, but
accepted postoperative radiotherapy (50 Gy). Of these six
patients, three with IMT of the maxillary sinus died of un-
controlled disease, including the two patients with
metastatic cervical lymph nodes. No evidence of local
recurrence was found in the clear margin of the six pa-
tients at the initial surgery. Furthermore, no local re-
currence was found in the three patients who had clear
margins following additional surgery. Nine patients
were alive at the time of the last follow-up.
Pathological findings
Microscopically, the tumor is composed of spindle cells
with various inflammatory cells, such as plasma cells,
lymphocytes, and occasional eosinophils. The compact
spindle cell pattern is characterized by a cellular prolifer-
ation of spindle cells with a fascicular or storiform archi-
tecture in a collagenous stroma. Nuclear atypia, frequent
mitoses, and atypical mitotic figures are infrequent in
some cases.
Immunohistochemical findings
All cases were immunohistochemically positive for vimen-
tin staining. The positive expression of α-smooth muscle
actin (α-SMA), desmin, and ALK was 67.7% (8/12), 25.0%
(3/12), and 33.3% (4/12), respectively. S-100, CD34, and
CD68 were negative in the tumor cells in all cases. Ki-67
expression was low (<5%) in all cases.
The rates of GLUT-1, HIF-1α, PI3K, and p-Akt ex-
pression were 41.7% (5/12), 50.0% (6/12), 33.3 (4/12),
and 41.7% (5/12), respectively (Table 3, Figure 2B-E). Of
the six patients who experienced recurrence, four
(67.7%) were positive for GLUT-1, five (83.3%) were
positive for HIF-1α, four (67.7%) were positive for
PI3K, and five (83.3%) were positive for p-Akt. Fisher’s
exact test revealed significant correlations between
lesion recurrence and the expression of PI3K (P = 0.01)
and p-Akt (P = 0.015); however, no significant cor-
relation was found between recurrence and the ex
pression of GLUT-1 (P = 0.242) or HIF-1α (P = 0.08).
The expression of GLUT-1, HIF-1α, PI3K, and p-Akt
was positive in the two patients with cervical lymph
Table 2 Clinicopathological findings and follow-up for the 12 studied cases of inflammatory myofibroblastic tumor
Case Sex Age Site CT, MRI, PET Treatment Recurrence Metastasis Follow-up
1 M 64 Larynx / Laryngeal fissure, complete
excision, clear margin
No No No evidence of disease
(68 months)
2 M 22 Tonsil / Tonsillectomy, clear margin No No No evidence of disease
(84 months)
3 M 33 Maxillare CT showed a softtissue mass in the
right maxillary alveolar bone. The local
bone of maxillary alveolar and inferior
wall of right maxillary sinus, and the
mass extended into the right maxillary
sinus, mild to moderate enhancement
on contrast-enhancement.
Local excision Yes, 6 years after first surgery. Total
maxillectomy was performed.
No No evidence of disease
(16 months after second
surgery)
4 M 48 Tongue CT showed a 3.7 × 1.7 cm irregular
softtissue mass in the left base of
tongue, strong enhancement on
contrast-enhanced imaging.
Local complete excision, clear
margin
No No No evidence of disease
(41 months)
5 F 61 Tonsil CT showed a 2.6 × 1.8 cm irregular soft
tissue mass between the left tonsil and
the base of the tongue with no
enhancement on contrast-enhanced
imaging.
Left tonsillectomy and mass
excision, clear margin
No No No evidence of disease
(23 months)
6 F 46 Hypopharynx MRI showed that a 1.3 × 2.2 cm mass in
the right pyriform sinus. Isointense and
slight hypointense on T1-weighted im-
aging, hyperintense on T2 -weighted
imaging, heterogeneous enhancement




Yes, 37 months after initial surgery.
Second surgery was performed via
lateral neck incision.
No No evidence of disease
(10 months after second
surgery)
7 F 46 Maxillary
sinus
CT showed a diffuse softtissue massin
the right maxillary sinus with
destruction of the maxillary bone
anteriorly and inwardly that extended




Yes, 2 months after initial treatment.
Then the patient received total
maxillectomy and exenteration +
radiotherapy postoperation.1 month





Died of disease (13 months
after initial treatment)
8 F 25 Mouth floor / Local excision, clear margin No No No evidence of disease
(132 months)
9 F 63 Maxillary
sinus
A homogeneous mass in the left
maxillary sinus on the CT scan.
Partial maxillectomy neck
dissection, 50 Gy radiotherapy was
performed.
8 months after initial treatment,
occurrence was occurred. Another




Died of disease (11 months
after first treatment)
10 F 48 Maxillary
sinus
CT showed a softtissue expansile mass
in the left maxillary sinus.
Partial maxillectomy +
corticosteroids
Recurrence 6 months after initial
treatment. Total maxillectomy +
corticosteroids.
No No evidence of disease
(70 months after first
treatment)
11 F 34 Maxillary
sinus
CT showed a softtissue expansile mass
in the left maxillary sinus extending to
the nasal septum
Caldwell-Luc operation Recurrence 1 month after first surgery.
Partial maxillectomy + oral prednisone.
Tumor was not contained.3 months
later, 60Gy radiotherapy also did not





















Table 2 Clinicopathological findings and follow-up for the 12 studied cases of inflammatory myofibroblastic tumor (Continued)
contain the tumor. Endoscopic surgery
and total maxillectomy did not control
the tumor.
Follow-up showed PET/CT showed high
FDG uptake in the left maxillary sinus.
12 F 43 Neck A 3 × 4 × 11 cm well-defined mass in
the right neck, hyperintense on T1,
hypointense on T2, heterogeneous en-
hancement on contrast-enhanced T1-
weighted MRI images. MRI findings sug-
gested neurogenic tumor. CT showed a
well-defined, heterogeneous mass in
the right neck, mild enhancementon
contrast-enhanced imaging.





















Figure 1 Magnetic resonance imaging revealed a 1.3 × 2.2-cm mass in the right pyriform sinus. (A) Signals were isointense and slightly
hypointense on the T1-weighted imaging, (B) hyperintense on T2-weighted imaging, and (C) heterogeneous enhancement was observed on the
contrast-enhanced T1-weighted MRI images. (D) The patient underwent complete resection via a lateral neck incision and achieved a clear
margin at second surgery.
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the patient who underwent PET/CT during follow-up.
Mean overall survival was 102 months (95% confi-
dence interval, 73 to 131) in our sample. The 5-year
overall survival probability was 72.9%. Univariate ana-
lyses revealed a significant correlation between survival
and GLUT-1 (P = 0.028), PI3K (P = 0.006), and p-Akt (P =
0.028) expression. The multivariate analysis revealed no
statistically significant relationship between survival and
levels of GLUT-1, HIF-1α, PI3K, and p-Akt.
Spearman’s rank correlation analysis revealed a signifi-
cant correlation between HIF-1α and PI3K expressionFigure 2 Positronemission tomography/computed tomography. (A) Hig
of (B) GLUT-1, (C) HIF-1α, (D) PI3Kand (E) p-Aktwas positive.(r = 0.707, P = 0.01) and between p-Akt and PI3K ex-
pression (r = 0.837, P = 0.001). No correlation was found
between the expression of GLUT-1 and HIF-1α, PI3K, or
p-Akt expression (P > 0.05).
IMTs of the head and neck are relatively rare [3], and
most previous reports have been case studies. Two rela-
tively large studies of IMTs of the head and neck con-
ducted by Ong et al. [2] in 28 patients and by Chen
et al. [21] in 10 patients reported a high recurrence rate.
Our findings are consistent with those series. Our recur-
rence rate was 50% (6/12), generally within 1 year after
the initial treatment, and the mean time to recurrenceh 2-fluoro-2-deoxy-D-glucoseuptake in the left maxillary sinus. Expression
Table 3 Results of Glut-1, HIF-1α, PI3K, and p-Akt and outcome in 12 inflammatory myofibroblastic tumors of head
and neck
Case Site Recurrence Metastasis Follow-up Expression of
Glut-1 HIF-1α PI3K p-Akt
1 Larynx No No No evidence of disease (68 months) − + − −
2 Tonsil No No No evidence of disease (84 months) + − − −
3 Maxillare Yes No No evidence of disease (88 months
after first surgery)
− − − +
4 Tongue No No No evidence of disease (41 months) − − − −
5 Tonsil No No No evidence of disease (23 months) − − − −
6 Hypopharynx Yes No No evidence of disease (47 months
after first surgery)
− + + +
7 Maxillary sinus Yes Metastasis to cervical lymph node Died of disease (13 months after initial
treatment)
+ + + +
8 Mouth floor No No No evidence of disease (132 months) − − − −
9 Maxillary sinus Yes Metastasis to cervical lymph node Died of disease (11 months after first
treatment)
+ + + +
10 Maxillary sinus Yes No No evidence of disease (70 months
after first treatment)
+ + − −
11 Maxillary sinus Yes No Died of disease (35 months after initial
treatment)
+ + + +
12 Neck No No No evidence of disease (13 months) − − − −
+, positive; −, negative.
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follow-up period was 52.1 months (range, 11 to 132 months).
Two patients (16.7%) developed cervical lymph node metas-
tases, three (25.0%) died as a result of the IMT, and nine pa-
tients were alive at the time of the last follow-up.
The clinical findings and pathological features that
predict the course of IMTs are poorly understood. In
our series, three patients with tumors in the maxillary
sinus died. Local excision had been performed in all of
the patients who experienced recurrence. Our results are
similar to those of Jiang et al. [3], who reported significant
correlations between histological atypicality and recur-
rence and metastasis. Ong and colleagues [2] reported that
tumor location, depth, cytology pattern, pseudocapsule
component, and mitotic figure did not significantly affect
time to relapse and overall survival. They argued that sur-
gical margin was the most significant and independent
predictor of local relapse [2]. However, other investigators
have reported that IMT location is associated with re-
currence [2-4]. Coffin et al. [4] reported that the re-
currence of IMTs in the abdominopelvic area was
higher than that in other locations. Ong and col-
leagues [2] suggested that the poor outcome associated
with IMTs of the maxillary sinus and nasal cavity
stemmed from the fact that lesions in these locations
could readily extend superiorly to Ohngren’s line and
involve the orbit and skull base. They hypothesized
that involvement of these vital organs restricted thesurgical resection, resulting in positive surgical mar-
gins. Although our sample size was small, our findings
support this hypothesis.
The results of previous investigations of possible mor-
phological and genetic prognostic indicators for IMTs
were inconclusive [2-4]. Ong et al. [2] found that immu-
nohistochemical biomarkers were not significantly corre-
lated with recurrence and prognosis. Coffin et al. [4] and
Jiang et al. [3] found that ALK reactivity was a favorable
prognostic indicator for IMT. We investigated molecular
biomarkers associated with IMTs of the head and neck
using immunohistochemistry to assess glucose metabol-
ism in the lesions. In this, the protein expression rates
were 41.7% for GLUT-1, 50.0% for HIF-1α, 33.3% for
PI3K, and 41.7% for p-Akt, and the recurrence of IMT
was significantly associated with PI3K and p-Akt expres-
sion. Although the expression of GLUT-1 and HIF-1α
was not significantly associated with recurrence, 67.7%
(4/6) of the patients were positive for GLUT-1 and
83.3% (5/6) were positive for HIF-1α. The expression of
GLUT-1, HIF-1α, PI3K, and p-Akt was positive in the
two patients who developed cervical lymph node metas-
tasis, the three patients who died from the IMT, and the
patient who underwent PET and CT during follow-up. In
a previous study, we found that GLUT-1, HIF-1, PI3K,
and p-Akt were expressed in a case of ceruminous aden-
oma [22]. Furthermore, we found that the rate of GLUT-1,
PI3K, and p-Akt protein in patients with adenoid cystic
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respectively [23].
In this series, the 5-year overall survival probability
was 72.9%. Univariate analysis revealed a significant cor-
relation between survival and the expression of GLUT-1,
PI3K, and p-Akt. Multivariable analysis revealed no
significant relationship between survival and GLUT-1,
HIF-1α, PI3K, or p-Akt levels. In a previous study, we
found a significant correlation between GLUT-1 and
HIF-1α (r = 0.504; P = 0.000) expression and suggested
that increased GLUT-1 expression was an independent
predictor of survival for laryngeal carcinoma [12]. More-
over, in cases of adenoid cystic cancer of the head and
neck we found significant correlations between the ex-
pression of GLUT-1 and PI3K, GLUT-1 and p-Akt, and
p-Akt and PI3K [23]. One possible explanation is that
the PI3K/Akt signal-transduction cascade regulates
HIF-1α expression [24], which can activate the tran-
scription of more than simply its target genes [25], in-
cluding GLUT-1. Alternatively, GLUT-1 expression may
be directly activated by the PI3K/Akt pathway, which has
been shown to promote GLUT-1 cell-surface trafficking
and activity [20]. However, in this study, we found signifi-
cant correlations only between HIF-1α and PI3K, and be-
tween p-Akt and PI3K expression. No correlation was
found between GLUT-1 expression and that of HIF-1α,
PI3K, or p-Akt. The absence of a significant correlation
between HIF-1α and proteins of PI3K/Akt pathway may
be attributable to our small sample size. Thus, further
studies of the relationship between GLUT-1 expression
and HIF-1α and proteins of PI3K/Akt pathway in IMTs of
the head and neck are warranted.Conclusions
Although our results are inconclusive, owing to small
sample size, we suggest that expression of PI3K and p-Akt
may play a role in the recurrence of IMTs of the head and
neck. Univariate analyses revealed significant correlations
between GLUT-1, PI3K, and p-Akt expression and sur-
vival. However, multivariate analysis did not find statisti-
cally significant relationships between survival and GLUT-1,
HIF-1α, PI3K, p-Akt expression. Further study is needed
to confirm our findings.Abbreviations
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